retatrutide clinical trial results 2024 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide study sees significant weight

Energy can dip early in treatment

It is the strategy most likely to produce a successful 12-month outcome

Semaglutide needs to be taken long-term to be effective for blood sugar management or weight loss

(Source: Long-term GLP-1 safety review, June 2026) There Is No Evidence Supporting a Hard Time Limit on Treatment A frequent patient concern is that GLP-1s cannot be safe indefinitely

We were quite surprised by the strength of the association between GLP-1 medication use and the lower risk of developing macular degeneration, says Benjamin Young, MD, a corresponding author and an assistant professor of ophthalmology at OHSU Health in Portland, Oregon

Evidence-Based Treatment Many top programs now offer GLP-1 medications such as: semaglutide tirzepatide Wegovy Zepbound These medications should only be prescribed after medical evaluation and provider review